Over the past decade, driven by the government's increased investment in the healthcare industry, China's healthcare market has experienced a phase of rapid development, and with the continuation of healthcare reform, the landscape of China's healthcare market will undergo fundamental changes. Zero2IPO Research Center believes that the future of the pharmaceutical industry as a whole will still maintain rapid growth, but the structure will be more optimized. Since the launch of the new healthcare reform, governments at all levels have increased their investment in the construction of medical facilities and equipment renewal, coupled with the steady rise in the volume of medical service consultations and treatments in China, China's medical device market has ushered in an era of rapid development. The fundamental use of drugs to support medical care will certainly be forced to raise the price of medical services, strong demand and favorable policies will promote the rapid growth of the medical services industry, mobile health care will drive the development of medical services and related medical device segments.

The golden age of the pharmaceutical industry has passed, and policy dividend is the key

In the aging population, the disease spectrum changes and drug upgrading continued to promote, the medium and long term growth trend of the biopharmaceutical industry remains unchanged, but the short and medium term, health insurance premium control, bidding price reductions, administrative price reductions, the efficiency of the approval of new drugs on the industry's development of a more profound impact; although the state of the pharmaceutical industry's regulatory policy is complex and changing, but behind the policy changes guiding the industry trends are still relatively clear, such as the strengthening of the rationality of the use of drugs, encouraging high generic drugs, and the development of the pharmaceutical industry. Rationality, encourage import substitution of high generic drugs, priority review of clinically needed generic drugs to optimize the competitive landscape of the industry.

Favorable policy & market demand, medical devices into the fast lane of development

Since the launch of the new healthcare reform in 2009, governments at all levels have increased investment in the construction of medical facilities and equipment renewal, coupled with the steady increase in the volume of medical services in China, China's medical device market has ushered in an era of rapid development. With the improvement of relevant regulations, the policy orientation of the Chinese government in the medical device industry has become clearer, that is, to gradually improve the efficiency of regulation, encourage innovation, especially domestic key innovations, and strengthen the quality and sex.

Medical service is medical reform, mobile medical will drive the development of related industries

The greater good in the process of health care reform is privatization (i.e., public hospital restructuring), medical services will continue to benefit from this longer cycle of industry change brought about by the system dividend. At present, medical services in the health care industry as a whole accounted for a relatively low, and basically no policy resistance, the policy environment is better than the pharmaceutical industry, the future space is huge. Under the high growth trend of the mobile healthcare market, the evolution of vertical solutions from horizontal applications to the value chain of mobile healthcare services will become the direction of industry development.